Polyrizon Ltd（PLRZ）资讯与事件PLRZPolyrizon Ltd

Polyrizon Completes Contracts for Nasarix Clinical Study

Polyrizon announced that it has completed contracting with the fourth and fifth clinical sites participating in its clinical study of Nasarix Allergy Blocker. With the execution of these final agreements, Polyrizon has completed the contracting with all five U.S. clinical sites selected for the study, marking an important operational milestone and moves the Nasarix program into study execution. The planned first-in-human study is a prospective, multicenter, randomized, single-blind, two-arm clinical trial designed to evaluate the efficacy, safety and tolerability of Nasarix in patients with seasonal allergic rhinitis. The study is designed to enroll up to 120 randomized patients, with subjects assigned in a 1:1 ratio to receive either Nasarix Allergy Blocker or an isotonic saline nasal spray control.

Polyrizon Completes Contracts for All Clinical Sites in NASARIX Study

Polyrizon has completed contracting with the fourth and fifth clinical sites participating in its clinical study of NASARIX Allergy Blocker. With the execution of these final agreements, Polyrizon has now completed the contracting process with all five clinical sites selected to participate in the study, marking an important operational milestone in the advancement of the NASARIX clinical program. The planned first-in-human study is a prospective, multicenter, randomized, single-blind, two-arm clinical trial designed to evaluate the efficacy, safety and tolerability of NASARIX in patients with seasonal allergic rhinitis. The study is designed to enroll up to 120 randomized patients, with subjects assigned in a 1:1 ratio to receive either NASARIX Allergy Blocker or an isotonic saline nasal spray control. The study's primary efficacy endpoint will evaluate the difference between the treatment groups in mean daily reflective Total Nasal Symptom Score over the first 14 treatment days. Safety assessments will include the frequency and severity of treatment-emergent adverse events as well as assessments of local and overall tolerability. Secondary efficacy measures are expected to include instantaneous Total Nasal Symptom Score, rhinoconjunctivitis-related quality of life, the number of symptom-free days, and use of permitted relief medication. Following completion of the clinical site contracting process, Polyrizon is advancing the study into the next stage of execution, including patient pre-screening activities and preparations for enrollment. Because the study evaluates seasonal allergic rhinitis under real-world allergen exposure conditions, patient enrollment is planned to coincide with the relevant allergy seasons. Local pollen counts and weather conditions will be monitored to assess airborne allergen exposure and support the timing of recruitment.